Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Pyxis Oncology, Inc. (NASDAQ: PYXS) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation therapeutics for patients battling difficult-to-treat cancers. Their pipeline focuses on innovative antibody-drug conjugates (ADCs) and immunomodulating agents. Pyxis Oncology aims to translate promising scientific insights into meaningful clinical benefits for cancer patients worldwide.
The headquarters serves as the central hub for Pyxis Oncology's research and development, clinical operations, corporate strategy, and administrative functions.
The facility is located in a prominent biotech hub and likely features modern laboratory and office spaces designed to support advanced biopharmaceutical research and foster collaboration among scientific and corporate teams.
Pyxis Oncology fosters a dynamic, science-driven work environment. The culture emphasizes innovation, collaboration, a patient-centric approach, and a sense of urgency in developing novel cancer treatments.
This central location is critical for executing the company's mission, housing key leadership, and providing the core infrastructure for its drug discovery, translational research, and clinical development programs.
While Pyxis Oncology is headquartered in the United States, its clinical development activities and collaborations may extend globally. The company engages with international clinical trial sites and research partners to advance its therapeutic pipeline, facilitating patient recruitment and gathering diverse data. This global operational scope for clinical trials is typical for biopharmaceutical companies aiming to bring novel treatments to a worldwide patient population, rather than maintaining numerous physical international corporate offices at its current stage.
35 Gatehouse Drive
Waltham
Massachusetts
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Pyxis' leadership includes:
Pyxis has been backed by several prominent investors over the years, including:
Pyxis Oncology has strategically strengthened its leadership team with key appointments over the past 12 months to enhance its development and operational capabilities as it progresses its clinical pipeline. No major executive departures have been publicly announced during this period.
Discover the tools Pyxis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Pyxis Oncology's email addresses likely follow common corporate patterns. The most probable formats include the first initial followed by the last name, or the full first name separated by a dot from the last name, using the company's domain pyxisoncology.com.
Common formats: [first_initial][last]@pyxisoncology.com (e.g., jdoe@pyxisoncology.com) or [first].[last]@pyxisoncology.com (e.g., jane.doe@pyxisoncology.com)
Format
jsmith@pyxisoncology.com
Example
80%
Success rate
GlobeNewswire • April 2, 2024
Pyxis Oncology announced the presentation of preclinical data for PYX-201, its antibody-drug conjugate targeting EDB fibronectin, at the American Association for Cancer Research (AACR) Annual Meeting 2024. The data highlighted PYX-201's potential in treating various solid tumors....more
GlobeNewswire • March 26, 2024
Pyxis Oncology reported its financial results for the fourth quarter and full year ended December 31, 2023. The company also provided an update on its corporate progress, including advancements in its clinical pipeline and key upcoming milestones....more
GlobeNewswire • February 20, 2024
Pyxis Oncology announced the appointment of Steve Monks, Pharm.D., as its new Chief Development Officer. Dr. Monks brings significant experience in oncology drug development to the role, aiming to advance Pyxis's pipeline programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Pyxis, are just a search away.